Bioethics

Position of the Biotechnology Industry Organization (BIO), regarding oversight of gene therapy

With the increasing computerization of medical records and the consolidation of the health care system, people have become more concerned about the potential threat to the confidentiality of individual health information.

BIO supports the creation of federal standards to protect the confidentiality of an individual's medical information, including the results of genetic testing.

The Biotechnology Industry Organization (BIO) supports national legislation to protect the confidentiality of all individually identifiable medical information. BIO believes that this medical information must be respected, treated confidentially and safeguarded from discriminatory misuse.

November 20 2013
BIO welcomes the opportunity to provide the views of its members on facilitating access to genetic resources and traditional knowledge and the sharing of benefits from their use...
November 16 2011
Recent reports have raised concerns about how clinical trials are being performed in other countries, particularly in the developing world...
July 7 2009
 BIO thanks the National Institutes of Health (NIH) for the opportunity to submit comments on the advanced notice of proposed rulemaking regarding conflict of interest in federally funded medical research, published in the Federal Register on May 8, 2009...
May 27 2009
The Biotechnology Industry Organization (BIO) thanks the National Institutes of Health (NIH) for the opportunity to submit comments on the draft guidelines for human stem cell research, published in the Federal Register on April 23, 2009...
June 6 2007
As President & CEO of the Biotechnology Industry Organization (BIO), I am writing to express BIO’s support for S. 5, the Stem Cell Research Enhancement Act...
November 17 2011
A timely and consistent regulatory process will ultimately result in medical treatments and cures for some of the most devastating and life-threatening diseases... 
December 16 2010
Research and development in synthetic biology is an evolution of biotechnology innovation that should be supported and encouraged by federal regulatory policies... 
September 29 2010
BIO President and CEO Jim Greenwood released the following statement on action by the U.S. Circuit Court of Appeals last night to stay the lower court’s injunction on federally funded embryonic stem cell research...
August 24 2010
BIO President and CEO Jim Greenwood issued the following statement today regarding the injunction issued yesterday by a U.S. District Court prohibiting the use of federal funds to support embryonic stem cell research...
May 24 2010
Achievement of a milestone in creating synthetic life in the form of a self-replicating cell from synthesized DNA has focused attention on the field of synthetic biology...